Tags

Type your tag names separated by a space and hit enter

Two Cases of De Novo Pathological Gambling Associated With Aripiprazole.
Clin Neuropharmacol. 2019 May/Jun; 42(3):101-102.CN

Abstract

OBJECTIVES

Pathological gambling can be potentiated by treatment with dopamine agonists. Aripiprazole, bearing a partial agonist activity at dopamine D2 and D3 receptors, has also been linked to such a behavioral aberration, usually on subjects predisposed with tendency of impulsive or addictive behaviors.

METHODS

Review of patient's medical records and literature review.

RESULTS

Two young patients' pathological gambling emerged simply due to exposure to aripiprazole, neither related to manic or psychotic symptoms nor with history of addictive or impulsive behaviors. Their pathological gambling disappeared soon after switching aripiprazole to other antipsychotics. One patient has tested such a relationship by reexposure to aripiprazole while his compulsion to gamble recurred.

CONCLUSIONS

In addition to previously recognized risk factors, pathological gambling might occur in young patients whose history did not reveal an addictive tendency while they were sensitive to the pharmacological effect, as well as adverse effects, of psychotropic agents.

Authors+Show Affiliations

Department of Psychiatry, National Taiwan University Hospital, Taipei.Department of Psychiatry, National Taiwan University Hospital, Yunlin Branch, Yunlin.No affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

31082834

Citation

Chen, Hui-Yi, et al. "Two Cases of De Novo Pathological Gambling Associated With Aripiprazole." Clinical Neuropharmacology, vol. 42, no. 3, 2019, pp. 101-102.
Chen HY, Ma CH, Liu CC. Two Cases of De Novo Pathological Gambling Associated With Aripiprazole. Clin Neuropharmacol. 2019;42(3):101-102.
Chen, H. Y., Ma, C. H., & Liu, C. C. (2019). Two Cases of De Novo Pathological Gambling Associated With Aripiprazole. Clinical Neuropharmacology, 42(3), 101-102. https://doi.org/10.1097/WNF.0000000000000342
Chen HY, Ma CH, Liu CC. Two Cases of De Novo Pathological Gambling Associated With Aripiprazole. Clin Neuropharmacol. 2019 May/Jun;42(3):101-102. PubMed PMID: 31082834.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Two Cases of De Novo Pathological Gambling Associated With Aripiprazole. AU - Chen,Hui-Yi, AU - Ma,Chia-Hao, AU - Liu,Chen-Chung, PY - 2019/5/15/entrez PY - 2019/5/15/pubmed PY - 2019/11/2/medline SP - 101 EP - 102 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 42 IS - 3 N2 - OBJECTIVES: Pathological gambling can be potentiated by treatment with dopamine agonists. Aripiprazole, bearing a partial agonist activity at dopamine D2 and D3 receptors, has also been linked to such a behavioral aberration, usually on subjects predisposed with tendency of impulsive or addictive behaviors. METHODS: Review of patient's medical records and literature review. RESULTS: Two young patients' pathological gambling emerged simply due to exposure to aripiprazole, neither related to manic or psychotic symptoms nor with history of addictive or impulsive behaviors. Their pathological gambling disappeared soon after switching aripiprazole to other antipsychotics. One patient has tested such a relationship by reexposure to aripiprazole while his compulsion to gamble recurred. CONCLUSIONS: In addition to previously recognized risk factors, pathological gambling might occur in young patients whose history did not reveal an addictive tendency while they were sensitive to the pharmacological effect, as well as adverse effects, of psychotropic agents. SN - 1537-162X UR - https://www.unboundmedicine.com/medline/citation/31082834/Two_Cases_of_De_Novo_Pathological_Gambling_Associated_With_Aripiprazole_ L2 - http://dx.doi.org/10.1097/WNF.0000000000000342 DB - PRIME DP - Unbound Medicine ER -